Relmada Therapeutics (RLMD) Income from Continuing Operations (2012 - 2026)
Relmada Therapeutics (RLMD) reported Income from Continuing Operations of 18501992.0 for Q1 2026, down 4.07% year-over-year from 19287280.92 in Q1 2025, and up 7.24% quarter-over-quarter from 19945881.0 in Q4 2025.
Relmada Therapeutics (RLMD) Income from Continuing Operations (2012 - 2026) Analysis & Trends
Relmada Therapeutics (RLMD) has 15 years of Income from Continuing Operations data on file, last reported at 18501992.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 18501992.0, down 4.07% year-over-year; the trailing twelve-month figure through Mar 2026 was 58428054.0 (up 23.33% YoY), and the FY2025 annual result was 57704211.0, up 28.19% from the prior year.
- Income from Continuing Operations improved to 18501992.0 in Q1 2026 per RLMD's latest filing, from 19945881.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 9899848.0 in Q2 2025 and troughed at 45512072.0 in Q2 2022.
- A 5-year average of 24492169.53 and a median of 21931972.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2025: Income from Continuing Operations sank 71.99% in 2022, then surged 54.5% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 38702420.0 in 2022, then soared by 33.93% to 25570094.0 in 2023, then gained by 27.96% to 18420912.0 in 2024, then slipped by 8.28% to 19945881.0 in 2025, then advanced by 7.24% to 18501992.0 in 2026.
- Business Quant data shows RLMD's Income from Continuing Operations at 18501992.0 in Q1 2026, 19945881.0 in Q4 2025, and 10080333.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Relmada Therapeutics | 581.07 Mn | 581.07 Mn | - | -18.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.50 Mn |
| Dec 31, 2025 | -19.95 Mn |
| Sep 30, 2025 | -10.08 Mn |
| Jun 30, 2025 | -9.90 Mn |
| Mar 31, 2025 | -17.78 Mn |
| Dec 31, 2024 | -18.42 Mn |
| Sep 30, 2024 | -22.15 Mn |
| Jun 30, 2024 | -17.86 Mn |
| Mar 31, 2024 | -21.93 Mn |
| Dec 31, 2023 | -25.57 Mn |
| Sep 30, 2023 | -21.37 Mn |
| Jun 30, 2023 | -24.66 Mn |
| Mar 31, 2023 | -26.95 Mn |
| Dec 31, 2022 | -38.70 Mn |
| Sep 30, 2022 | -38.74 Mn |
| Jun 30, 2022 | -45.51 Mn |
| Mar 31, 2022 | -38.30 Mn |
| Dec 31, 2021 | -34.18 Mn |
| Sep 30, 2021 | -42.65 Mn |
| Jun 30, 2021 | -26.46 Mn |